Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.63 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.63 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1438746 | 0.90 | GNAI3 (0.58) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 | |
| SCHEMBL2325698 | 0.86 | GNAI3 (0.66) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21640532 | 0.83 | CYP3A4 (0.55) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 | |
| SCHEMBL22652025 | 0.83 | NAAA (0.63) | CYP3A4ALDH1A1KDM4EHPGDUSP2 | |
| SCHEMBL30807297 | 0.83 | GNAI3 (0.58) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 | |
| SCHEMBL2331949 | 0.82 | REN (0.53) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 | |
| SCHEMBL1438748 | 0.81 | GNAI3 (0.84) | GNAI3GNAO1GNAI1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL21640827 | 0.81 | CYP3A4 (0.53) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 | |
| SCHEMBL4555068 | 0.80 | GNAI3 (0.94) | GNAI3GNAO1GNAI1GAA | |
| SCHEMBL2535622 | 0.80 | GNAI3 (0.57) | GNAI3GNAO1GNAI1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352732-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO Ý4, 3-D¨PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | Merck Patent GmbH (DE) | 2011-08-10 | — | — | EP | claimed |
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-09-29 | — | — | US | disclosed |
| WO-2009098282-A1 | LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY | NOVASAID AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| EP-1440071-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | Pfizer Japan Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | ENPP2, PLA2G4A, PLA2G4B | GNAI3 1577/4885GNAO1 1123/4885GNAI1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.